Trovagene, Inc. Announces First Quarter 2014 Financial Results - 21 News Now, More Local News for Youngstown, Ohio -

Trovagene, Inc. Announces First Quarter 2014 Financial Results

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Trovagene, Inc.

SAN DIEGO, May 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2014.

A molecular diagnostics company with unique intellectual property around the discovery that DNA and RNA, present in urine, can be diagnostic of cancer and infectious disease

"Our focus is to demonstrate the benefit of our precision cancer monitoring platform through research collaborations and expansion of our product offerings," said Antonius Schuh, Ph.D., chief executive officer of Trovagene. "In the first quarter, we established two new partnerships to further validate our platform, presented clinical data at the AACR annual meeting, and made the first of our next-generation sequencing-based applications available through our CLIA laboratory. We look forward to advancing our technology and continuing to meet our goals and objectives throughout 2014."

First Quarter 2014 Financial Results

For the first quarter ended March 31, 2014, Trovagene reported a net loss of $3.2 million, or $0.17 per share, as compared to a net loss of $1.1 million, or $0.07 per share, for the three months ended March 31, 2013. The increase in net loss is primarily due to increased operating expenses and changes in the fair market value of derivative instruments during the first quarter of 2014 as compared to the prior year comparable period.

Cash and Cash Equivalents

Trovagene had cash and cash equivalents of $22.9 million on March 31, 2014, as compared to $25.8 million on December 31, 2013.

Review of First Quarter Announcements Demonstrate Continued Progress in Development Programs

Reiteration of 2014 Goals and Objectives

  • Conduct additional clinical studies at major oncology centers and through collaborations with integrated healthcare networks
  • Present and publish clinical results for studies using Trovagene's precision cancer monitoring platform as they become available
  • Complete CLIA development and release additional urine-based assays to expand Trovagene's precision cancer monitoring platform for the detection and monitoring of multiple clinically actionable oncogene mutations in parallel
  • Enter into additional R&D collaborations with pharmaceutical companies
  • Expand and enter into new partnerships with strategic diagnostic and life science companies

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA and RNA in urine.  The company's technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene's precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on Trovagene's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement.  Investors should read the risk factors set forth in Trovagene's Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

(Financial Information to Follow)

Contact

Investor Relations


Media Relations

David Moskowitz and Amy Caterina

Investor Relations


Ian Stone

Account Director

Trovagene, Inc.


Canale Communications, Inc.

858-952-7593


619-849-5388

ir@trovagene.com


ian@canalecomm.com

 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Selected Financial Information

Consolidated Condensed Statements of Operations

(in thousands, except for per share amounts)





Three Months Ended

March 31,



2014


2013



(unaudited)


(unaudited) 








Revenues


$

111


$

119






Operating expenses:





Research and development


1,443


802

Sales and marketing


570


361

General and administrative


1,358


1,346

Total operating expenses


3,371


2,509






Operating loss


(3,260)


(2,390)






Other income (expense):


37



Change in fair market value of derivative instruments


33


1,279

Net loss and comprehensive loss



(3,190)



(1,111)






Preferred stock dividend


(9)


(6)

Net loss and comprehensive loss attributable  to common stockholders


$

(3,199)


$

(1,117)






Basic and diluted net loss per share


$

(0.17)


$

(0.07)






Weighted average shares outstanding - basic and diluted


18,903


15,510






 

Trovagene, Inc. and Subsidiaries

(A Development Stage Company)

Consolidated Condensed Balance Sheet Information

(in thousands)




March 31,

2014


December 31,

2013



(unaudited)








Cash and cash equivalents


$

22,871


$

25,837

Other assets


728


568

Property and equipment, net


860


751

Total assets


$

24,459


$

27,156






Current portion of long-term debt


$

201


$

198

Accounts payable, accrued expenses and other liabilities


1,831


1,811






Long-term debt, less current portion


275


323

Derivative financial instruments


4,399


4,432

Stockholders' equity


17,753


20,392

Total liabilities and stockholders' equity


$

24,459


$

27,156






Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

©2012 PR Newswire. All Rights Reserved.

  • More From wfmj.comMore>>

  • 6 hurt when truck hits Dairy Queen near Pittsburgh

    6 hurt when truck hits Dairy Queen near Pittsburgh

    Friday, July 25 2014 1:01 AM EDT2014-07-25 05:01:26 GMT
    PITTSBURGH (AP) - Authorities say six people were injured and a gas line was damaged after a truck crashed into a Dairy Queen in suburban Pittsburgh. The Pittsburgh Post-Gazette said the incident occurred shortly before 3 p.m. Thursday in Penn Hills. A witness tells the newspaper that she was able to help an employee get out through a window after a cash register fell onto her. That employee, the manager and four men in the truck were taken to hospitals. The newspaper says firefighters secur...More >>
    PITTSBURGH (AP) - Authorities say six people were injured and a gas line was damaged after a truck crashed into a Dairy Queen in suburban Pittsburgh. The Pittsburgh Post-Gazette said the incident occurred shortly before 3 p.m. Thursday in Penn Hills. A witness tells the newspaper that she was able to help an employee get out through a window after a cash register fell onto her. That employee, the manager and four men in the truck were taken to hospitals. The newspaper says firefighters secur...More >>
  • UPDATED

    Ohio State marching band director fired

    Ohio State marching band director fired

    Thursday, July 24 2014 8:49 PM EDT2014-07-25 00:49:54 GMT
    Ohio State University fired the director of its celebrated marching band on Thursday amid allegations he knew about and ignored "serious cultural issues," some involving rituals where students were pressured to march in their underwear or participate in sexually themed stunts.More >>
    Ohio State University fired the director of its celebrated marching band on Thursday amid allegations he knew about and ignored "serious cultural issues," some involving rituals where students were pressured to march in their underwear or participate in sexually themed stunts.More >>
  • Witness: Teen's plane didn't show obvious distress

    Witness: Teen's plane didn't show obvious distress

    Thursday, July 24 2014 7:38 PM EDT2014-07-24 23:38:16 GMT
    The family of an Indiana teenager who crashed in the Pacific Ocean during an around-the-world flight says he knew the risks and had prepared for them.More >>
    A man who saw a plane flown by an Indiana teen who was killed during an around-the-world flight attempt says the aircraft was flying low but didn't show any obvious signs of distress before diving into the ocean off...More >>
Powered by WorldNow
All content © Copyright 2000 - 2014 Worldnow and WFMJ. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms